Corrigendum: Long term outcome of Aldosteronism after target treatments (Scientific Reports (2016) 6 (32103) DOI: 10.1038/srep32103);Long term outcome of Aldosteronism after target treatments

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wu, Vin Cent ^a   Wang, Shuo Meng ^a   Chang, Chia Hui ^b   Hu, Ya Hui ^b   Lin, Lian Yu ^a   Lin, Yen Hung ^a   Chueh, Shih Chieh Jeff ^c   Chen, Likwang ^d   Wu, Kwan Dun ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI TZU CHI HOSPITAL   (Taiwan)

^c CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

MINERALOCORTICOID ANTAGONIST;

ADRENALECTOMY; ADULT; EPIDEMIOLOGY; FEMALE; HUMAN; HYPERALDOSTERONISM; MALE; MIDDLE AGED; MORTALITY; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; TAIWAN; TREATMENT OUTCOME;

ADRENALECTOMY; ADULT; FEMALE; HUMANS; HYPERALDOSTERONISM; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; TAIWAN; TREATMENT OUTCOME;

EID: 84985916244     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep45249     Document Type: Erratum

References (44)

1. Funder, J. W. et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93, 3266-3281 (2008).
2. Milliez, P. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology 45, 1243-1248 (2005).
3. Reincke, M. et al. Observational study mortality in treated primary aldosteronism: the German Conn's registry. Hypertension 60, 618-624 (2012).
4. Lin, Y. H. et al. Adrenalectomy improves increased carotid intima-media thickness and arterial stiffness in patients with aldosterone producing adenoma. Atherosclerosis 221, 154-159 (2012).
5. Wu, V. C. et al. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment. J Hypertens 29, 1778-1786 (2011).
6. Catena, C. et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 168, 80-85 (2008).
7. Lin, Y. H. et al. Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism. J Hypertens 30, 1606-1613 (2012).
8. Miyake, Y. et al. Prognosis of primary aldosteronism in Japan: results from a nationwide epidemiological study. Endocrine journal 61, 35-40 (2014).
9. Catena, C. et al. Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. Horm Metab Res 42, 440-445 (2010).
10. Lewis, N. J., Patwell, J. T., Briesacher, B. A. The role of insurance claims databases in drug therapy outcomes research. PharmacoEconomics 4, 323-330 (1993).
11. Wu, P. C., Wu, C. J., Lin, C. J., Wu, V. C., National Taiwan University Study Group on Acute Renal Failure, G. Long-term risk of upper gastrointestinal hemorrhage after advanced AKI. Clin J Am Soc Nephrol 10, 353-362 (2015).
12. Wu, V. C. et al. Long-term risk of coronary events after AKI. J Am Soc Nephrol 25, 595-605 (2014).
13. Wang, W. J. et al. The impact of acute kidney injury with temporary dialysis on the risk of fracture. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 29, 676-684 (2013).
14. Wu, P. C. et al. Pentoxifylline Decreases Dialysis Risk in Patients With Advanced Chronic Kidney Disease. Clinical pharmacology and therapeutics 98, 442-449 (2015).
15. Cheng, C. L., Kao, Y. H., Lin, S. J., Lee, C. H., Lai, M. L. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiology and drug safety 20, 236-242 (2011).
16. Lin, C. C., Lai, M. S., Syu, C. Y., Chang, S. C., Tseng, F. Y. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. Journal of the Formosan Medical Association = Taiwan yi zhi 104, 157-163 (2005).
17. Wu, V. C. et al. Administrative data on diagnosis and mineralocorticoid receptor antagonist prescription identified patients with primary aldosteronism in Taiwan. Journal of clinical epidemiology 67, 1139-1149 (2014).
18. Wu, C. S., Lai, M. S., Gau, S. S., Wang, S. C., Tsai, H. J. Concordance between Patient Self-Reports and Claims Data on Clinical Diagnoses, Medication Use, and Health System Utilization in Taiwan. PloS one 9, e112257 (2014).
19. WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD). Available from http://www.whocc.no/atc-ddd-index/Accessed 18th March 2016 (2015).
20. Wu, V. C. et al. Association of kidney function with residual hypertension after treatment of aldosterone-producing adenoma. Am J Kidney Dis 54, 665-673 (2009).
21. Catena, C. et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 50, 911-918 (2007).
22. Chiang, C. E. et al. 2015 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension. J Chin Med Assoc 78, 1-47 (2015).
23. Wu, V. C. et al. Endothelial Progenitor Cells in Primary Aldosteronism: A Biomarker of Severity for Aldosterone Vasculopathy and Prognosis. J Clin Endocrinol Metab 96, 3175-3183 (2011).
24. Wu, V. C. et al. Prevalence and clinical correlates of somatic mutation in aldosterone producing adenoma-Taiwanese population. Scientific reports 5, 11396 (2015).
25. Woo, M. J., Reiter, J. P., Karr, A. F. Estimation of propensity scores using generalized additive models. Statistics in medicine 27, 3805-3816 (2008).
26. Wu, K. D. et al. Zona fasciculata-like cells determine the response of plasma aldosterone to metoclopramide and aldosterone synthase messenger ribonucleic acid level in aldosterone-producing adenoma. J Clin Endocrinol Metab 80, 783-789 (1995).
27. Guder, G. et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 115, 1754-1761 (2007).
28. Miyake, Y. et al. Prognosis of primary aldosteronism in Japan: results from a nationwide epidemiological study. Endocrine journal 61, 35-40 (2013).
29. Reimel, B. et al. The management of aldosterone-producing adrenal adenomas-does adrenalectomy increase costs? Surgery 148, 1178-1185; discussion 1185 (2010).
30. Rossi, G. P. et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 62, 62-69 (2013).
31. Indra, T. et al. Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism. J Renin Angiotensin Aldosterone Syst 16, 1109-1117 (2015).
32. Ori, Y. et al. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone. Nephrol Dial Transplant 28, 1787-1793 (2013).
33. Williams, J. S. Evolving research in nongenomic actions of aldosterone. Curr Opin Endocrinol Diabetes Obes 20, 198-203 (2013).
34. Ezekowitz, J. A., McAlister, F. A. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. European heart journal 30, 469-477 (2009).
35. Strauch, B. et al. Adrenalectomy improves arterial stiffness in primary aldosteronism. Am J Hypertens 21, 1086-1092 (2008).
36. Mulatero, P. et al. Roles of clinical criteria, computed tomography scan, and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes. J Clin Endocrinol Metab 93, 1366-1371 (2008).
37. Wu, V. C. et al. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment. J Hypertens 29, 1778-1786 (2011).
38. Wu, C. H. et al. Effect of Treatment on Body Fluid in Patients with Unilateral Aldosterone Producing Adenoma: Adrenalectomy versus Spironolactone. Scientific reports 5, 15297 (2015).
39. Rossi, G. P. et al. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension 51, 1366-1371 (2008).
40. Sang, X. et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China. J Hypertens 31, 1465-1471; discussion 1471-1462 (2013).
41. Douma, S. et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 371, 1921-1926 (2008).
42. Chao, C. T. et al. Diagnosis and management of primary aldosteronism: an updated review. Annals of medicine 45, 375-383 (2013).
43. Levesque, L. E., Hanley, J. A., Kezouh, A., Suissa, S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340, b5087 (2010).
44. Concato, J., Shah, N., Horwitz, R. I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342, 1887-1892 (2000).